APUS (Apimeds Pharmaceuticals Us) Treasury Stock: $0.00 Mil (As of Mar. 2026)


APUS Apimeds Pharmaceuticals Us Inc APUS
14 GF Score
Price $0.72
! 3 Warning Signs
View Full Analysis

What is Apimeds Pharmaceuticals Us Treasury Stock?

Apimeds Pharmaceuticals Us APUS -2.04% 14 Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Apimeds Pharmaceuticals Us's treasury stock for the quarter that ended in Mar. 2026 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Apimeds Pharmaceuticals Us Treasury Stock Historical Data

* Premium members only.

The historical data trend for Apimeds Pharmaceuticals Us's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apimeds Pharmaceuticals Us Treasury Stock Chart

Apimeds Pharmaceuticals Us Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
0.00 0.00 0.00 0.00 0.00

Apimeds Pharmaceuticals Us Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
APUS
14GF Score
Apimeds Pharmaceuticals Us Inc APUS
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apimeds Pharmaceuticals Us Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $0.00 Mil mean?
Apimeds Pharmaceuticals Us (APUS) has a Treasury Stock of $0.00 Mil as of Mar. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Apimeds Pharmaceuticals Us and its competitors.
Is Apimeds Pharmaceuticals Us' Treasury Stock too high?
Apimeds Pharmaceuticals Us' current Treasury Stock is $0.00 Mil. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Treasury Stock compare to KAYS and BIOE?
Apimeds Pharmaceuticals Us' Treasury Stock of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Drug Manufacturers company?
A good Treasury Stock depends on the Drug Manufacturers industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Apimeds Pharmaceuticals Us and its competitors. Apimeds Pharmaceuticals Us's current Treasury Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Treasury Stock of $0.00 Mil. The current Treasury Stock is $0.00 Mil. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score

Get the complete analysis for APUS

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price